公开(公告)号：EP3885035A1

公开(公告)日：2021-09-29

申请号：EP20215355.7

申请日：2020-12-18

Applicant: Korea Institute of Science and Technology

Inventor： KIM, Jongsik ,  HA, Heon Phil

IPC: B01J21/06 ,  B01J23/00 ,  B01J37/20 ,  B01J37/28

Abstract: Provided is a catalyst for a Fenton system, a catalyst structure including the same, and a Fenton system using the same. The catalyst includes one or more species of d 0 -orbital-based or non-d 0 -orbital-based catalyst including NO 3 - /SO4 2 -/H 2 PO 4 - /HPO 4 2- /PO4 3- functional groups on the surface thereof.

公开(公告)号：EP3872909A1

公开(公告)日：2021-09-01

申请号：EP20187646.3

申请日：2020-07-24

Applicant: Korea Institute of Science and Technology

Inventor： JANG, Jong Hyun ,  PARK, Hyun Seo ,  PARK, Hee-Young ,  LIM, Katie Heeyum ,  KIM, Oh Sub ,  KIM, Hyoung-Juhn ,  KIM, Jin Young ,  YOO, Sung Jong ,  HENKENSMEIR, Dirk ,  LEE, So Young

IPC: H01M4/86 ,  H01M4/88 ,  H01M4/90 ,  C01B32/15 ,  C01B32/18 ,  H01M4/92 ,  H01M10/6567

Abstract: Disclosed are a catalyst electrode for a fuel cell, a method for fabricating the catalyst electrode, and a fuel cell including the catalyst electrode. The presence of an ionomer-ionomer support composite in the catalyst electrode prevents the porous structure of the catalyst electrode from collapsing due to oxidation of a carbon support to avoid an increase in resistance to gas diffusion and can stably secure proton channels. The presence of carbon materials with high conductivity is effective in preventing the electrical conductivity of the electrode from deterioration resulting from the use of a metal oxide in the ionomer-ionomer support composite and is also effective in suppressing collapse of the porous structure of the electrode to prevent an increase in resistance to gas diffusion in the electrode. Based on these effects, the fuel cell exhibits excellent performance characteristics and prevents its performance from deteriorating during continuous operation.

公开(公告)号：EP3822606A1

公开(公告)日：2021-05-19

申请号：EP19834451.7

申请日：2019-07-10

Applicant: Korea Institute of Science and Technology ,  Center of Human-Centered Interaction for Coexistence

Inventor： KIM, Jinseok ,  YANG, Sungwook ,  JANG, Min Su ,  KIM, Jun Sik ,  KANG, Kyumin ,  YOU, Bum-Jae

IPC: G01L5/24 ,  G01L11/02 ,  G01L1/24

Abstract: Embodiments relate to a torsion sensor device which measures a degree of torsion of a measurement object by using a fiber Bragg gratings (FBG) sensor, the sensor device comprising: an FBG sensor including a sensing unit formed in one section of an elongated optical fiber; and a fixing device for fixing and supporting the FBG sensor to cause displacement of the FBG sensor according to motion of the measurement object, wherein the fixing device includes a bending prevention member to enable the sensing unit to have torsion displacement without bending displacement, according to the motion of the measurement object.

公开(公告)号：EP3649244A2

公开(公告)日：2020-05-13

申请号：EP18828686.8

申请日：2018-07-03

Applicant: Korea Institute of Science and Technology

Inventor： CHUNG, Hak Suk ,  JI, Yuhyun ,  AN, Jinsu ,  KWON, Ick Chan ,  YANG, Eun Gyeong

IPC: C12N15/74 ,  C12N9/14 ,  C12N9/16 ,  C12P19/04

公开(公告)号：EP3567048A1

公开(公告)日：2019-11-13

申请号：EP18736762.8

申请日：2018-01-04

Applicant: Kyungpook National University Industry-Academic Cooperation Foundation ,  Korea Institute of Science and Technology

Inventor： KIM, So Youn ,  SEO, Jun Young ,  KIM, In San

IPC: C07K7/06 ,  C07K14/79 ,  C12N9/68 ,  A61K38/48 ,  A61K47/66

Abstract: The present invention relates to: a fusion peptide comprising a thrombus-targeting peptide, ferritin fragment and a thrombolytic peptide; and a use thereof and, more specifically, to: a fusion peptide in which a thrombus-targeting peptide, ferritin fragment and a thrombolytic peptide are sequentially linked; a composition for preventing or treating thrombotic disorders, containing the same as an active ingredient; a method for treating thrombotic disorders; and a therapeutic use. According to the present invention, CLT-sFt-µPn DCNC as a novel plasmin-based thrombolytic nanocage has: an effect of targeting a site at which thrombus is present; a low sensitivity to inhibitors present in the circulatory system; pharmacological activity strongly destroying both arterial and venous thrombi; and no side effects of bleeding, and thus can be very useful in developing an agent for preventing or treating thrombotic disorders.

公开(公告)号：EP2031613B1

公开(公告)日：2019-10-09

申请号：EP08014462.9

申请日：2008-08-13

Applicant: Korea Institute of Science and Technology

Inventor： Jo, Seong Mu ,  Kim, Dong Young ,  Jang, Sung Yeon ,  Park, Nam Gyu ,  Yi, Byoung Hong

IPC: H01G9/20

公开(公告)号：EP2811746B1

公开(公告)日：2019-10-02

申请号：EP12867103.9

申请日：2012-08-08

Applicant: Korea Institute of Science and Technology

Inventor： KIM, Sung Kyu ,  YOON, Ki Hyuk

IPC: H04N13/302 ,  G02B27/22 ,  H04N13/31 ,  H04N13/351 ,  H04N13/366

公开(公告)号：EP3536790A1

公开(公告)日：2019-09-11

申请号：EP17866684.8

申请日：2017-11-03

Applicant: Korea Institute of Science and Technology

Inventor： PAN, Cheol-Ho ,  SHIN, Bok-Kyu ,  ERDENE-OCHIR, Erdenedolgor ,  KIM, Sang Min

IPC: C12N15/79 ,  C12P21/00 ,  C07K14/485 ,  A61K8/64 ,  A61Q19/00 ,  A61Q19/08

Abstract: The present specification relates to: a vector comprising a promoter of SEQ ID NO: 1 and a human epidermal growth factor (hEGF) exon, which includes a gene coding for hEGF; microalgae transformed with the vector; a method for producing a hEGF protein and/or a PTD-hEGF protein by using the transformed microalgae; and a cosmetic composition containing the hEGF and/or PTD-hEGF protein(s) produced according to the production method. The hEGF and PTD-hEGF proteins, produced according to an aspect of the present invention, can fundamentally block the risk of endotoxicity, unlike a hEGF protein produced from conventional E. coli, thereby being usable as a raw material for eco-friendly cosmetic products.

公开(公告)号：EP2150278B1

公开(公告)日：2019-06-12

申请号：EP08741523.8

申请日：2008-04-23

Applicant: Korea Institute of Science and Technology

Inventor： KWON, Ick-Chan ,  CHOI, Kui-Won ,  KIM, Kwang-Meyung ,  YOUN, In-Chan ,  KIM, Jong-Ho ,  PARK, Kyeong-Soon

IPC: A61K49/12 ,  A61K41/00 ,  A61P35/00 ,  A61K47/61 ,  A61K47/69

公开(公告)号：EP3459567A1

公开(公告)日：2019-03-27

申请号：EP18164779.3

申请日：2018-03-28

Applicant: Korea Institute of Science and Technology

Inventor： KIM, Kwangmeyung ,  KWON, Ick Chan ,  PARK, Juho

IPC: A61K47/65 ,  A61K47/69

Abstract: Disclosed is a drug conjugate as a prodrug that is degraded by cathepsin B specifically expressed in tumor tissues to release doxorubicin. The drug conjugate can form self-assembled nanoparticles. In addition, the drug conjugate specifically responds to and is activated in tumor cells. Therefore, the use of the drug conjugate eliminates the incidence of side effects (for example, cell damage and apoptosis) during the course of cancer prevention or treatment.